Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357584 | 0.77 | PTPN2 (0.74) | PTK2NPC1TP53MAPTRAB9A | |
| SCHEMBL15440489 | 0.77 | HPGD (0.53) | PTK2HPGDNPC1TP53MAPT | |
| SCHEMBL13270043 | 0.76 | PTK2 (0.71) | PTK2NPC1TP53MAPTRAB9A | |
| SCHEMBL13139581 | 0.76 | PTK2 (0.57) | PTK2HPGDNPC1TP53MAPT | |
| SCHEMBL5092793 | 0.75 | PTK2 (1.00) | PTK2NPC1MAPTRAB9AMAPK8 | |
| SCHEMBL1680689 | 0.74 | PTK2 (0.73) | PTK2NPC1TP53MAPTRAB9A | |
| SCHEMBL19494280 | 0.74 | PTK2 (0.68) | PTK2NPC1MAPTRAB9AMAPK8 | |
| SCHEMBL941528 | 0.74 | ALDH1A1 (0.47) | NPC1TP53MAPTRAB9AMAPK8 | |
| SCHEMBL11535897 | 0.74 | GPR35 (0.61) | HPGDNPC1RAB9AMAPK10ALDH1A1 | |
| SCHEMBL11946878 | 0.73 | PTK2 (0.71) | PTK2NPC1TP53MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2611812-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030894-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-4234581-A | ANTIALLERGENS | MEAD JOHNSON & COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-4159377-A | ANTIALLERGENS | MEAD JOHNSON & COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4054656-A | ASTHMA, HAY FEVER, FOODS | MEAD JOHNSON & COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | PTK2 224/4885HPGD 769/4885NPC1 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.